Dexcom Up Over 50% for the Year and Momentum on Track for 2015

Dexcom shares are up over 50% for the year on four FDA approvals. CEO Terry Gregg tells TheStreet’s Jill Malandrino the company is answering the unmet needs of diabetics with superior technology and getting product approvals through the FDA in record time. The quick turnaround allows Dexcom to get more accuracy and connectivity with the products, particularly SHARE which is the first product to hit the market with real-time, omnichannel monitoring. In terms of accuracy Dexcom has moved from a 13% MARD (Mean Absolute Relative Difference) measurement to 9%, the first and only CGM system to get below 10%. This is key because it gets Dexcom closer to a dosage claim eliminating finger sticks, a goal the company is working with the FDA on now. Looking to 2015, Gregg says Dexcom is expanding its sales force and geographic coverage with new partnerships like Johnson & Johnson, Tandem Diabetes, Insulet and Asante.